The investment seeks to track the investment results (before fees and expenses) of the Wells Fargo Hybrid and Preferred Securities Floating and Variable Rate Index. The fund will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is a m... The investment seeks to track the investment results (before fees and expenses) of the Wells Fargo Hybrid and Preferred Securities Floating and Variable Rate Index. The fund will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is a market capitalization-weighted index designed to track the performance of preferred stock, as well as certain types of hybrid securities that are functionally equivalent to preferred stocks, that are issued by U.S.-based or foreign issuers and that pay a floating or variable rate dividend or coupon. It is non-diversified. Show more
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases...
LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the...
Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...
LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases...
LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases...
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases...
Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients hospitalized with COVID-19 Conference call today at...
LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory...
LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory...
LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.14 | -0.576368876081 | 24.29 | 24.45 | 24.12 | 618777 | 24.2612964 | SP |
4 | -0.34 | -1.38832176399 | 24.49 | 24.56 | 24.12 | 552035 | 24.29251037 | SP |
12 | -0.52 | -2.10782326713 | 24.67 | 24.67 | 24.12 | 385285 | 24.37592619 | SP |
26 | 0.15 | 0.625 | 24 | 24.67 | 23.43 | 378335 | 24.25897161 | SP |
52 | 0.93 | 4.00516795866 | 23.22 | 24.67 | 23.1429 | 373919 | 23.97654086 | SP |
156 | -1.63 | -6.32273079907 | 25.78 | 25.9 | 20.875 | 433998 | 23.19622836 | SP |
260 | -1.79 | -6.90053970702 | 25.94 | 26.5 | 13.33 | 401493 | 23.74818793 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.